# Intent to Sole Source Award, Anavorx Distribution LLC, IHS, Phoenix Area, Anascorp Scorpion Antivenom Canonical: https://abierto.us/opportunities/ihs1489441pao - Solicitation number: IHS1489441-PAO - Notice type: Special notice - Status: Awarded to Rare Disease Therapeutics, Inc. - Department: Department of Health and Human Services - Agency: Indian Health Service - Contracting office: Phoenix Area Indian Health SVC (75H712) - NAICS: 325412 Pharmaceutical Preparation Manufacturing - Place of performance: Phoenix, Arizona - County: Maricopa County (FIPS 04013). https://abierto.us/counties/maricopa-county-az-04013 - City: Phoenix. https://abierto.us/cities/phoenix-az-0455000 - First posted: June 24, 2024 - Last posted: June 24, 2024 - SAM.gov: https://sam.gov/workspace/contract/opp/d830effc025b4cbea9113ced3f070b29/view ## Description This is a notification of an intent to award a sole source contract to Anovorx Distribution LLC. under NAICS code 325412 – Pharmaceutical Preparation and Manufacturing for the Indian Health Services for a period of performance from June 20, 2024 to April 14, 2025 under the authority of FSS Limited Source Justification, Orders Against FSS, FAR FAR 8.405-6(a)(1)(i)(B)), Only One Source. The Phoenix Area Pharmacy Consultant is requesting for a Blanket Purchase Agreement (BPA) Sole Source Award to Anovorx Distribution, LLC, distributor for Rare Disease Therapeutic Inc FSS #36F79718D0404, to provide Anascorp, Centroides (Scorpion) Immune F(ab’)2(Equine), Injection on a as needed basis from June 20, 2024 to April 14, 2025 for the clinics and hospitals under the Phoenix Area. Anovorx will provide a minimum of 3 vials and a maximum of 76 vials for this period. Anovorx Distribution, LLC is the only contractor to offer ANASCORP [Centruroides (Scorpion) Immune F(ab’)2 (Equine) Injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. Anascorp is composed of venom-specific F(ab’)2 fragments of immunoglobulin G (IgG) that bind and neutralize venom toxins, facilitating redistribution away from target tissues and elimination from the body. Physician will initiate treatment with Anascorp Injection as soon as possible after scorpion sting in patients who develop clinically important signs of scorpion envenomation, including but not limited to loss of muscle control, roving or abnormal eye movements, slurred speech, respiratory distress, excessive salivation, frothing at the mouth and vomiting. Anascrop Injection is widely used by the Southwest Regional Indian Health Services Hospitals and Clinics including Tucson Area, Albuquerque Area and Phoenix Area. If you can provide the supplies requested, all responsible sources may submit a capability statement, which shall be considered by the Agency and may be e-mailed to donovan.conley@ihs.gov referencing notice number IHS1489441-PAO by 4:00 PM July 1, 2024. A determination by the Government not to compete this proposed contract acquisition based upon responses to the notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. This notice does not obligate the Government to award a contract or otherwise pay for information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed. Information provided will be used to assess tradeoffs and alternatives available for the potential requirement and may lead to the development of a solicitation. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. Any solicitation resulting from the analysis of information obtained will be announced to the public in Federal Business Opportunities in accordance with the FAR Part 5. However, responses to this notice will not be considered adequate responses to a solicitation. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). ## Award on USAspending - Recipient: Rare Disease Therapeutics, Inc. (UEI M7B1ABSZJKX8) - Contract: 75H71224A00013 under 36F79718D0404 - Obligated: $0.00 - Competition: Full and Open Competition, 1 offers received - Link: solicitation number IHS1489441PAO equals the FPDS solicitation identifier; same awarding office 75H712 (high confidence) - Record: https://www.usaspending.gov/award/CONT_IDV_75H71224A00013_7527/ ## Publications - June 24, 2024: Special notice, due July 1, 2024 at 7:00 PM EDT. Notice d830effc025b4cbea9113ced3f070b29. https://sam.gov/workspace/contract/opp/d830effc025b4cbea9113ced3f070b29/view ## Points of contact - Donovan Conley, Donovan.Conley@ihs.gov, 6023645174 - Jeremy Steel, jeremy.steel@ihs.gov, 6023645264 --- Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/ihs1489441pao.